ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Pairwise Poised to Revolutionize Agriculture with Industry-Leading Fulcrum™ Platform following $40M Series C Funding

Durham, N.C., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Pairwise, a technology company pioneering gene editing to improve plant breeding in specialty and commodity crops, has closed a $40M Series C funding round led by Deerfield Management. Multiple returning investors, including Aliment Capital and Leaps by Bayer, are joined by new investor and global ag technology leader Corteva, Inc. (NYSE: CTVA), through its Corteva Catalyst platform, further signaling the promise and anticipated benefits of gene editing in agricultural applications.

Delivering Transformative Improvements in Food and Agriculture

Investments from this funding round will be used to scale Pairwise’s innovative product pipeline, including seedless berries and pitless cherries, as well as advance its industry-leading Fulcrum™ Platform. Pairwise’s new seedless blackberry variety, announced in June, will deliver an improved eating experience for consumers and, in concert with compact architecture and thornless traits, bring added benefits to farm workers, growers, and the environment as well.

“We started Pairwise in the early days of CRISPR to accelerate innovation across agriculture, enabling the cultivation of crops that are more adaptive to climate change, and more nutritious and convenient for consumers, all while bolstering grower economics,” said Tom Adams, Pairwise Co-Founder and CEO. “This new investment will enable us to expand the impact of our proprietary Fulcrum Platform as we continue to lead this transformation with our proven ability to deliver novel solutions that address the most pressing challenges in agriculture today.”

“Using their novel tools, Pairwise has delivered game-changing edits in plant varieties across consumer and big-acre crops in just a few short years,” said Cam Wheeler, Partner at Deerfield Management and Pairwise Chairman of the Board. “We believe that the precision, speed, and safety of gene editing is poised to transform agriculture, and our ongoing investment reflects our confidence in Pairwise as the clear leader in this space.”

Corteva Chief Technology and Digital Officer Sam Eathington said, “We view gene editing as a critical solution to drive climate resilience across agriculture and global food systems. Pairwise is an obvious choice for our investment to help accelerate innovation through gene editing in fruit, vegetables, and specialty crops. And as leaders in gene editing ourselves, Corteva’s ultimate aim is to work with Pairwise to unlock the impact of this technology to help solve climate challenges and produce the food, fiber and fuel required to meet the needs of a growing global population.”

In parallel to Corteva’s equity investment in Pairwise, the two companies have entered into a five-year joint venture collaboration that will focus on accelerating the pace of gene edited technologies and developing improved products that are more resilient to future climate conditions.

Corteva’s investment in Pairwise is being made through Corteva Catalyst, the company’s new investment and partnership platform launched to boost agricultural R&D and sustainable food production innovations.

Trailblazing a New Era in Accelerated Innovation

Pairwise was founded by proven business leaders, preeminent experts, and inventors of early gene-editing technologies. Using industry-leading knowledge of plant genetics, a broad suite of CRISPR tools, and high-impact editing techniques like multiplexing, Pairwise has delivered multiple products with differentiated plant genetics across significant crops, including corn, soy, wheat, canola, leafy greens, blackberries, and more. As one of the only companies in this space to launch commercially viable products to date, Pairwise introduced the first CRISPR food to North America – a blend of superfood mustard greens that eat like lettuce, edited to dial down the wasabi-like pungency for people looking for healthier salad options than what are available in the marketplace today. After laying the important commercial groundwork, the company entered into an exclusive product licensing agreement with Bayer to further develop and sell 10 varieties of Pairwise-edited greens at scale, and to develop and breed for new varieties with the technology. Additionally, after delivering 27 novel traits to Bayer’s pipeline under an initial five-year partnership, the two companies entered a second, multi-year collaboration to focus on developing a gene-edited version of short-stature corn to offer farmers better protection for their crops given improved sustainability in high winds and challenging weather conditions, better access during the season, and higher yields.

The Pairwise Fulcrum™ Platform includes company-developed gene editing tools for cutting, base editing, and templated editing – a toolbox that enables not only turning a characteristic on or off, like removing a plant’s thorns to enable easier fruit harvesting, but also “tuning” it – like a dimmer switch to dial a trait up or down, such as creating a new type of corn with up to 20% more kernel rows. Using Pairwise’s novel editing tools, scientists can precisely tailor a wide range of genetic variation to develop new, distinctive plant varieties much faster and more effectively than through conventional breeding. In concert with its industry-leading tools, Pairwise’s intellectual property enables a straightforward path to product commercialization.

"Our technology licensing agreements provide secured IP and increase shareholder value. And our proprietary suite of technologies – our Fulcrum Platform – is enabling us to unlock transformative improvements in global agriculture,” added Adams. “Our product-development partnerships with global agriculture leaders, Corteva and Bayer, underscored by investments from both Corteva Catalyst and Leaps by Bayer, are an incredible validation of our technology and an important signal that gene editing will play a major role in improving agriculture innovation moving forward.”

Institutions interested in learning about Pairwise investment or licensing opportunities may contact the company at www.Pairwise.com.

# # #

About Pairwise:
Pairwise is pioneering the application of gene editing technology in food and agriculture. The company brings together leaders in agriculture and tech to harness transformative genomic technologies to create innovative new products that benefit society. Pairwise is working to develop new varieties of fruits, vegetables, and large-acre crops, and to partner with organizations that seek to deliver innovation across the plant-based economy. Backed by industry leading investors Deerfield, Aliment Capital, Leaps by Bayer, Temasek, and Corteva Catalyst, Pairwise raised $40 million in a successful funding round in September 2024, bringing total fundraising to $155 million. The company was co-founded by the company’s CEO Dr. Tom Adams and agriculture innovator Dr. Haven Baker, with scientific co-founders J. Keith Joung, Lead Translator at Arena BioWorks; David Liu, Director of the Merkin Institute of Transformative Technologies in Healthcare, and Vice-Chair of the Faculty at the Broad Institute of Harvard and MIT; and Feng Zhang, McGovern Investigator and a professor at MIT. For more information, visit Pairwise.com, and learn more about the differentiating Pairwise Fulcrum™ Platform here.


Diana Souder
Pairwise
communications@pairwise.com
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.